Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment optimization of cetuximab in metastatic colorectal cancer based on 89Zr-cetuximab PET
2010-021943-41Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal adenocarcinoma (mCRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Amsterdam University Medical Center. Primary endpoint: Demonstration of 89Zr-cetuximab uptake in non-hepatic tumour lesions. Started Oct 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal adenocarcinoma (mCRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2010-021943-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021943-41.